Futura Medical plc (LSE:FUM), the company behind Eroxon, the first over-the-counter topical gel for erectile dysfunction, released half-year results on 1 September 2026 that expose a Business at a genuine crossroads. Revenue for the six months to 30 June 2026 climbed to £1.62m, though £1.40m of that figure stemmed from a settlement with departing US partner Haleon, and the board has cautioned that cash will only stretch to roughly October 2026 without new funding.

Against that backdrop, Futura has won European clearance for a faster-acting version, Eroxon Intense, reported encouraging user data for its female sexual health gel WSD4000, and handed off US distribution to a new partner. With a Market Value of barely £2m, the pressing question is whether the pipeline can attract funding before time runs out.

 

Interim results: a settlement boosts the headline while cash runs toward October

Interim results for the six months to 30 June 2026 showed revenue of £1.62m, up from £1.00m in the same period of 2025. Excluding the £1.40m Haleon settlement, underlying revenue — mostly US Eroxon royalties — was just £0.21m. The operating loss narrowed to £1.20m from £6.72m, aided by the settlement and a 17% reduction in pre-exceptional administrative costs to £2.19m. Pre-tax loss came in at £1.18m (H1 2025: £6.69m), with basic loss per share of 0.20p (H1 2025: 2.17p).

Cash totalled £1.24m at 30 June 2026 and £1.06m at 31 July 2026, with the Haleon settlement received in August. Directors stated that “material uncertainties exist which may cast significant doubt on the Group’s ability to continue as a going concern,” yet prepared the accounts on a going-concern basis given ongoing funding initiatives and wider strategic options, while acknowledging “no certainty as to the timing, terms, value or outcome.”

Chief executive Alex Duggan characterised the half as “a period of significant strategic progress for Futura as we continued to execute our strategy, strengthen our portfolio and enhance the value of our key assets.” The company also disclosed a post-period claim from a former adviser relating to the Haleon termination, which it is contesting.

 

What Futura Medical does

Futura Medical (LSE:FUM) is an AIM-listed developer of topically applied gel formulations targeting sexual health. Its flagship product, Eroxon (MED3000), is a drug-free gel for erectile dysfunction, classified as a medical device and available without a prescription through licensing partners — Cooper Consumer Health across the European Economic Area and the UK, and Haleon in the United States until June 2026.

Revenue streams include product supply, royalties from partner sales, and historically, milestone payments. The United States generated £1.61m of H1 2026 revenue, including the settlement, whereas EU and UK partners produced no new sales as they worked through existing stock. The pipeline behind Eroxon includes Eroxon Intense, a faster-acting version, and WSD4000, a gel platform targeting female sexual dysfunction — a category where management says no over-the-counter treatment has yet won regulatory approval in any major market.

 

From £13.9m to £1.7m: the revenue reset behind the numbers

The half-year figures only make sense in light of a turbulent 2025. Unaudited full-year results published on 29 April 2026 showed revenue for the year to 31 December 2025 of £1.7m, an 88% drop from £13.9m in 2024, when milestone payments and initial stocking orders had inflated sales. The group flipped from a £1.2m operating profit to a £9.1m operating loss, which included £3.22m of asset impairments, with basic loss per share of 2.78p against Earnings of 0.43p previously. Net Assets fell from £8.96m to £2.81m.

A trading update on 19 September 2025 had already cut 2025 revenue guidance to £1.3m–£1.4m from market expectations of roughly £5m. Futura raised £2.75m gross in November 2025 by placing 275 million shares at 1p — roughly 54.5% below the prior closing price — leaving cash of £3.4m at 31 December 2025. No Dividend has been paid.

 

Catalysts: a new US partner, Eroxon Intense and WSD4000

The most immediate shift is commercial. On 29 June 2026, Futura announced Haleon’s US licence had terminated early, with Haleon paying a $1.9m termination fee and transferring Marketing materials and inventory. Market Performance Group (MPG) assumed US commercial control from 1 September 2026, earning commission on sales while Futura retains control of promotional spending. Management believes this “hybrid R&D and commercial model” gives Futura a larger share of future sales growth, following a disappointing October 2024 launch under Haleon.

Product developments could follow. Eroxon Intense secured EU MDR and UKCA clearance on 31 July 2026, allowing Cooper Consumer Health to launch it across Europe and the UK; FDA clearance is expected in the fourth quarter of 2026, with production beginning in the first quarter of 2027.

WSD4000 could prove the bigger opportunity. Data released on 30 June 2026 showed 78% of 228 women in a four-week home-use trial reported improved overall sexual function, and a separate 33-woman placebo-controlled crossover study found the gel statistically superior to placebo for arousal, genital sensation and lubrication. Futura is planning a pivotal study by the end of 2026, subject to funding, with a target launch from early 2028, and says early partnering discussions have already generated interest. New Eroxon partners are also being sought in China, Korea, Taiwan and Turkey.

 

Risks: funding, dilution and a revoked European patent

Funding remains the overriding risk. With £1.06m of cash at 31 July plus the £1.40m Haleon receipt, the board’s own runway estimate points to around October 2026. With shares trading at roughly 0.4p according to Stockopedia data on 2 September 2026, well below November’s 1p placing price, any additional Equity raise could prove heavily dilutive. The board has also referenced “wider strategic options,” which could include asset disposals.

Intellectual property presents a second concern. On 7 July 2026, the European Patent Office’s Opposition Division revoked European Patent EP 3934624B1, which covers MED3000. Futura is appealing, and the patent stays enforceable during an appeal process expected to run 18 to 24 months or longer, though an unfavourable final outcome would erode European exclusivity.

Commercial execution remains unproven. Underlying revenue of just £0.21m in the first half underscores how small Eroxon’s Royalty income has become, and MPG has yet to record a sale. Eroxon Intense still requires FDA clearance, WSD4000 needs a funded pivotal trial plus regulatory approval, and the disputed adviser claim adds a further, as-yet unquantified, uncertainty.

 

Outlook

Futura Medical heads into autumn with more clinical and regulatory milestones behind it than at any point since Eroxon’s launch — yet with less cash to show for it. Watch first for any funding announcement or strategic transaction, given the board’s own timetable suggests only weeks of runway remain. Beyond that, key markers include early US sell-through under MPG, an FDA decision on Eroxon Intense in the fourth quarter, Cooper Consumer Health’s European rollout, and whether a partner emerges to fund the WSD4000 pivotal study. Until the financing question is resolved, the promise of the pipeline and the fragility of the Balance Sheet will keep pulling in opposite directions.